Search results
Results from the WOW.Com Content Network
[1] [2] It has been gaining popularity over the last few decades and was approved in Europe in 2013 and the Food and Drug Administration (FDA) in April 2014. [3] The purpose of the hypoglossal nerve stimulator is to relieve tongue base obstruction during sleep by stimulating the tongue to protrude during inspiration (i.e., inhale).
BrainPort is a technology whereby sensory information can be sent to one's brain through an electrode array which sits atop the tongue. [1] It was initially developed by Paul Bach-y-Rita as an aid to people's sense of balance, particularly of stroke victims. Bach-y-Rita founded Wicab in 1998. [2] [3] [4]
“The exciting discovery is that Lag3 is already the target of an FDA-approved cancer drug called nivolumab/relatlimab, which uses antibodies to block the activity of Lag3,” the study authors ...
In 2004, a pulsed electromagnetic field system was approved by the FDA as an adjunct to cervical fusion surgery in patients at high risk for non-fusion. [6] On 8/9 September 2020 the FDA recommended to shift PEMF medical devices from the Class 3 category to a Class 2 status. [ 7 ]
For premium support please call: 800-290-4726 more ways to reach us
The U.S. Food and Drug Administration (FDA) has approved imatinib as first-line treatment for Philadelphia chromosome-positive CML, both in adults and children. The drug is approved in multiple contexts of Philadelphia chromosome-positive CML, including after stem cell transplant, in blast crisis, and newly diagnosed. [12]
(Reuters) -Johnson & Johnson said on Thursday the U.S. Food and Drug Administration had approved its antibody-based therapy for patients with a difficult-to-treat type of blood cancer. The therapy ...
Talimogene laherparepvec is delivered by injecting it directly into tumors, thereby creating a systemic anti-tumor immune response. [2]In the US, talimogene laherparepvec is FDA approved to treat Stage IIIb-IVM1c melanoma patients for whom surgical intervention is not appropriate and with tumors which can be directly injected; the EMA approved population in Europe is for Stage IIIb-IVM1a.